Tao Wei, Zheng Hai-Qun, Fu Ting, He Zhuo-Jing, Hong Yan
a Institute of Bioengineering, Zhejiang Academy of Medical Sciences , Hangzhou , Zhejiang , P. R. China.
Hum Vaccin Immunother. 2017 Aug 3;13(8):1818-1822. doi: 10.1080/21645515.2017.1331191. Epub 2017 Jun 12.
Adjuvants are essential for enhancing vaccine potency by improving the humoral and/or cell-mediated immune response to vaccine antigens. This study was performed to evaluate the immuno-enhancing characteristic of N-(2-hydroxy) propyl-3-trimethylammonium chitosan chloride (HTCC), the cationically modified chitosan, as an adjuvant for hepatitis E virus (HEV) recombinant polypeptide vaccine. Animal experiments showed that HTCC provides adjuvant activity when co-administered with HEV recombinant polypeptide vaccine by intramuscularly route. Vaccination using HTCC as an adjuvant was associated with increases of the serum HEV-specific IgG antibodies, splenocytes proliferation and the growths of CD4CD8 T lymphocytes and IFN-γ-secreting T lymphocytes in peripheral blood. These findings suggested that HTCC had strong immuno-enhancing effect. Our findings are the first to demonstrate that HTCC is safe and effective in inducing a good antibody response and stimulating Th1-biased immune responses for HEV recombinant polypeptide vaccine.
佐剂对于通过改善对疫苗抗原的体液免疫和/或细胞介导的免疫反应来增强疫苗效力至关重要。本研究旨在评估阳离子修饰的壳聚糖N-（2-羟基）丙基-3-三甲基氯化铵（HTCC）作为戊型肝炎病毒（HEV）重组多肽疫苗佐剂的免疫增强特性。动物实验表明，HTCC与HEV重组多肽疫苗通过肌肉注射途径共同给药时具有佐剂活性。使用HTCC作为佐剂进行疫苗接种与血清HEV特异性IgG抗体增加、脾细胞增殖以及外周血中CD4CD8 T淋巴细胞和分泌IFN-γ的T淋巴细胞生长有关。这些发现表明HTCC具有很强的免疫增强作用。我们的发现首次证明HTCC在诱导良好抗体反应和刺激针对HEV重组多肽疫苗的Th1偏向免疫反应方面是安全有效的。
